Scholars Central

Conference abstractPublished 2 Jul 2018

The protective efficacy of Zika polyclonal antibodies against lethal Zika virus infection in Ifnar1-/- mouse model

Authors: Shantha Kodihalli, Ayo Yila Simon, Emilie Branch, Hongyu Qiu, Sujan Shresta

Emergent BioSolutions, Canada; La Jolla Institute for Allergy & Immunology, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Zika virus (ZIKV) infection during pregnancy has become a global public health concern due to its ability to cause severe congenital infections. There are no licensed vaccines or therapeutics available for ZIKV infections. To address this need, a human polyclonal Zika Immune Globulin product (ZIKV-IG) is being developed for prophylaxis of ZIKV infection in at-risk populations, including women of childbearing potential and pregnant women. To evaluate the efficacy, groups of Ifnar1-/- mice were infected with lethal doses ZIKV (FSS13025 strain) and treated with various doses of ZIKV-IG. Mice were monitored daily for body weights, clinical signs, and mortality for 21 days. In another separate study, the dose-ranging effect of ZIKV-IG on the viral load in target tissues was analyzed on days 3 and 7 using qRT-PCR and focus forming assay. ZIKV-IG administered after lethal infection provided a significant survival benefit in a dose-dependent manner. Mice treated with higher doses of ZIKV-IG (10, 50 mg/kg) provided a statistically significant survival of 87.5 to 100% in comparison to 0% in PBS controls. A similar response was observed in the viral load analyses with the highest dose providing significant reductions in target tissues including the brain, kidney, liver, sciatic nerve, serum and spleen. The 2.0 mg/kg and 0.5 mg/kg (lower dose levels) did not confer any reasonable protection in terms of survival or reduction in viral load. The efficacy of ZIKV-IG has been successfully demonstrated in a well-characterized model of Zika disease. Results of these studies demonstrate that ZIKV-IG given at 50 mg/kg in a post-exposure setting significantly enhanced survival over control. Additionally, the treatment prevented virus dissemination into target tissues. These results clearly demonstrate the potential of ZIKV-IG for post-exposure prophylaxis of human ZIKV infections.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Virology & Mycology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalVirology & Mycology
  • SubjectInfectious Diseases
  • SubjectMicrobiology
  • BylineArticles whose byline prints “Shantha Kodihalli”
  • BylineArticles whose byline prints “Ayo Yila Simon”
  • BylineArticles whose byline prints “Emilie Branch”
  • BylineArticles whose byline prints “Hongyu Qiu”
  • BylineArticles whose byline prints “Sujan Shresta”